Document is current
Any future updates will be listed below
-
Authors
Peluso, Marisa O https://orcid.org/0000-0002-7025-0393
Adam, Ammar
Armet, Caroline M
Zhang, Li
O’Connor, Rachel W
Lee, Benjamin H
Lake, Andrew C
Normant, Emmanuel
Chappel, Scott C
Hill, Jonathan A
Palombella, Vito J
Holland, Pamela M
Paterson, Alison M
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03512340 at ClinicalTrials.govDocuments that mention this clinical trial
The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a
https://doi.org/10.1136/jitc-2019-000413
Novel treatments in B cell non-Hodgkin’s lymphomas
https://doi.org/10.1136/bmj-2020-063439
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Tumor-associated macrophages in multiple myeloma: advances in biology and therapy
https://doi.org/10.1136/jitc-2021-003975
-
Funding
Funding for this research was provided by:
Surface Oncology, Inc. (N/A)
- License Information
